Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
20.5.2021 00:14:00 EEST | Business Wire | Press release
Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021.
“We look forward to presenting data from across Incyte’s oncology portfolio and partner programs at this year’s ASCO Annual Meeting,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data being presented during this congress, including new three-year data from the L-MIND study of tafasitamab in relapsed or refractory diffuse large B-cell lymphoma as well as results of the OPTIC study of ponatinib in chronic phase-chronic myeloid leukemia, underscore our continued focus on advancing science to help meet patients’ needs.”
Key abstracts accepted by ASCO include:
Oral Presentations
Ponatinib
OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)1 (Abstract #7000. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Poster Discussions
Tafasitamab
Long-Term Analyses from L-MIND, a Phase 2 Study of Tafasitamab (MOR208) Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)2 (Abstract #7513. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
Capmatinib
Capmatinib in MET Exon 14-Mutated, Advanced NSCLC: Updated Results from the GEOMETRY Mono-1 Study3 (Abstract #9020. Session: Lung Cancer—Non-Small Cell Metastatic.)
ePosters
Capmatinib
Capmatinib Efficacy in Patients with NSCLC Identified as METex14 Using an NGS-Based Liquid Biopsy Assay: Results from the GEOMETRY Mono-1 Study3 (Abstract #9111. Session: Lung Cancer—Non-Small Cell Metastatic.)
Patient-Reported Outcomes in Capmatinib-Treated Patients with METex14-Mutated Advanced NSCLC: Results from the Phase 2 GEOMETRY Mono-1 Study3 (Abstract #9056. Session: Lung Cancer—Non-Small Cell Metastatic.)
Phase 1b/2 Study of Capmatinib Plus Gefitinib in Patients with EGFR-Mutated, MET-Dysregulated Non–Small Cell Lung Cancer who Received Prior Therapy: Final Overall Survival and Safety3 (Abstract #9048. Session: Lung Cancer—Non-Small Cell Metastatic.)
Pemigatinib
Pemigatinib for Previously Treated Locally Advanced/Metastatic Cholangiocarcinoma (CCA): Update of FIGHT-202 (Abstract #4086. Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary.)
Retifanlimab
Phase 2 Study of Retifanlimab (INCMGA00012) in Patients (Pts) with Selected Solid Tumors (POD1UM-203) (Abstract #2571. Session: Developmental Therapeutics—Immunotherapy.)
Ruxolitinib-Parsaclisib Combination Studies
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naïve Myelofibrosis (Abstract #TPS7058. Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.)
Tafasitamab
A Phase 3 Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) (Abstract #TPS7568. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
First-MIND: A Phase 1b, Open-Label, Randomized Study to Assess Safety of Tafasitamab (tafa) or Tafa + Lenalidomide (LEN) in Addition to R‑CHOP in Patients with Newly Diagnosed DLBCL2 (Abstract #7540. Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.)
For full session details and data presentation listings, please see the ASCO21 online program at https://meetinglibrary.asco.org. Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, June 4, 2021 at 9:00 a.m. ET.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s or partner company’s ongoing clinical development pipeline, and whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain and other third-party providers, and development and discovery operations; determinations made by the FDA and other regulatory authorities outside of the United States; the Company’s dependence on its relationships with its collaboration partners; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2020 and the quarterly report on Form 10-Q for the quarter ended March 31, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.
1 Takeda-sponsored abstract.
2 MorphoSys-sponsored abstract.
3 Novartis-sponsored abstract.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005952/en/
Contact information
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
T964 Named as Uptime Institute Business Partner to Power Iraq’s Digital Infrastructure29.7.2026 10:02:00 EEST | Press release
Uptime Institute and Tech964 Holding Limited (T964), Iraq’s leading digital infrastructure company, today announced a landmark strategic partnership to accelerate Iraq’s digital transformation. The partnership combines the world’s leading authority in digital infrastructure standards with the company building the critical infrastructure underpinning Iraq’s digital economy. The agreement was signed at the U.S. Chamber of Commerce U.S.-Iraq Business Summit on July 17, 2026, during the official U.S. visit of Iraqi Prime Minister Ali Al-Zaidi, at a historic summit that produced more than 50 agreements valued at over USD $60 billion and marked a powerful new era of economic cooperation between the United States and Iraq. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260728066813/en/ T964 named as Uptime Institute Business Partner to power Iraq's digital infrastructure, landmark agreement signed at U.S. Chamber of Commerce U.S.-
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants29.7.2026 10:00:00 EEST | Press release
PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant strengthening of its governance. The company is strengthening the structure of its Board of Directors and Scientific Advisory Board to support the upcoming Phase 2 entry of its most advanced drug candidate, ARTHRELIS (treatment of gout flares), and to accelerate the preclinical development of ENGRAFTIS (treatment of poor graft function following bone marrow transplantation). The Board of Directors of PK MED welcomes four key new members: François Romaneix, appointed Chairman of the Board of Directors. Senior Partner at Truffle Capital, former CEO of the French National Authority for Health (HAS), and former Deputy CEO of the Institut Pasteur, he brings his strategic vision for market access and healthcare corporate governance. Isabelle Buckle, PhD, Board Member. With more than three decade
ELFA Vape Aerosols Less Harmful Than Cigarette Smoke: Study29.7.2026 10:00:00 EEST | Press release
Levels of 17 constituents in aerosols from ELFA, a pod system vape by ELFBAR, are undetected or substantially lower than those in cigarette smoke, reveals the latest peer-reviewed study published by iScience, a scientific journal. Aerosols in this study are generated by facilities under standardized laboratory conditions. The tests involve 17 cigarette smoke-related analytes during vaporization of vape liquid from ELFA’s pods in four flavors, including Super Tobacco, Spearmint, Strawberry Ice and Watermelon. Findings indicate that adult smokers completely transitioning to ELFA pod system could reduce, or even eliminate, their exposure to multiple harmful constituents compared with consuming combustible cigarettes. “This study adds to the growing scientific evidence supporting the effective role vaping products play in reducing, or even eliminating, exposure to harmful chemical substances for adult smokers,” said an ELFBAR spokesperson. “Providing adult users with quality cessation alte
OpenGate Capital Executes Agreement to Acquire Merak, the Global Rail HVAC Business of Knorr-Bremse29.7.2026 09:00:00 EEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Merak, the global rail HVAC business of Knorr-Bremse, a publicly listed German industrial company. Terms of the transaction were not disclosed. Headquartered in Getafe, Spain, Merak is a leading global provider of HVAC systems for rail vehicles, with facilities across Spain, Austria, Australia, the United States, China and India. The company offers a comprehensive portfolio of HVAC solutions spanning original equipment, aftermarket services, spare parts, system modernization and overhaul. Built on more than 60 years of engineering expertise, Merak serves a global installed base and maintains long standing relationships with many of the world's leading rolling stock manufacturers. "Merak is a high quality business with a market leading position, differentiated technology and a global customer base built over decades," said Joshua Adams, Partner at OpenGate Ca
Bureau Veritas: Delivering on Our Commitments With Higher Sequential Organic Growth in Q2 and Continuous Margin Improvements29.7.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): H1 2026 key figures1 › Revenue of EUR 3,258.4 million in H1 2026, up 2.1% year-on-year and up 5.0% organically (with a sequential improvement in Q2 2026 at 5.5% organic growth), › Adjusted operating profit of EUR 506.5 million, up 3.1% versus EUR 491.5 million in H1 2025, representing an adjusted operating margin of 15.5%, up 15 basis points year-on-year and up 29 basis points at constant currency, › Operating profit of EUR 430.8 million, down 16.0% versus EUR 513.1 million in H1 20252, › Adjusted net profit of EUR 303.8 million, up 3.9% versus EUR 292.4 million in H1 2025, › Adjusted EPS stood at EUR 0.68 in H1 2026, with a 4.8% increase on a reported basis versus H1 2025 (EUR 0.65 per share) and 9.8% at constant currency, › Attributable net profit of EUR 237.9 million, down 26.2% versus EUR 322.3 in H1 2025, › Free Cash Flow of EUR 157.7 million, up 3.2% organically, and down 6.1% year-on-year due to forex evolutions, › Adjusted net debt/EBITDA ratio stoo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom